A Phase 3 interventional study of Phentolamine Ophthalmic Solution 0.75% and Phentolamine Ophthalmic Solution Vehicle (Placebo) in Dim Light Vision Disturbances, sponsored by Opus Genetics, Inc. Completed at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Opus Genetics, Inc · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objectives of this study are:
Placebo-controlled, double-masked, multiple-dose, Phase 3 study in approximately 160 randomized subjects with DLD (approximately 136 that are evaluable for efficacy), evaluating safety and efficacy of Nyxol in subjects with DLD following administration of Nyxol once daily (QD) at or near bedtime (at 8PM to 10PM) in both eyes (OU) for 14 days.
Following the successful completion of screening, each subject will be stratified by iris color (light/dark irides) and will then be randomized to treatment (masked) 1:1, Nyxol or placebo (vehicle).
Treatment (Nyxol or placebo) will be administered in both eyes (OU) by the subjects at or near bedtime each day.
At the first visit subjects will be screened for study eligibility.
Treatment visits will occur 2 times: Day 8 (+1 day)/Visit 2 and Day 15 (+1 day)/Visit 3. mLCVA evaluations shall be performed on each of these days.
A follow-up visit (Visit 4) phone call will occur 1 to 3 days after Visit 3.
At select sites OPD Scan measurements will be made using wavefront abhermettry.
Opus Genetics, Inc is the lead sponsor of 17 studies on the registry; 4 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Ophthalmic:
Systemic:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One drop in both eyes at or near bedtime (8PM to 10PM)
Drug: Phentolamine Ophthalmic Solution 0.75%
One drop in both eyes at or near bedtime (8PM to 10PM)
Drug: Phentolamine Ophthalmic Solution Vehicle (Placebo)
0.75% phentolamine ophthalmic solution (Nyxol), a non-selective alpha-1 and alpha-2 adrenergic antagonist
Also known as: Nyxol, Nyxol®
Topical sterile ophthalmic solution
Percent of Subjects With 3 Lines mLCVA Improvement in Study Eye
Percent of subjects with ≥ 15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (≥3 lines) of improvement in the study eye compared to baseline in monocular mLCVA at Day 8
Time frame: 8 days
Percent of Subjects With mLCVA Improvement in Study Eye
Percent of subjects with ≥ 5, ≥ 10, and ≥ 15 ETDRS letters (≥ 1, ≥ 2, and ≥ 3 lines, respectively) improvement compared to baseline in mLCVA at Day 8 (excluding the primary endpoint)
Time frame: up to 15 days
Percent of Subjects With Photopic Low Contrast Visual Acuity (pLCVA) and mHCVA Improvement in Study Eye
Percent of subjects with ≥ 5, ≥ 10, and ≥ 15 ETDRS letters (≥ 1, ≥ 2, and ≥ 3 lines, respectively) improvement compared to baseline in pLCVA and mHCVA at Day 8 and Day 15
Time frame: up to 15 days
Change From Baseline in Study Eye Mesopic Pupil Diameter (PD)
Change from baseline in study eye mesopic PD
Time frame: up to 15 days
Percent Change From Baseline in Study Eye Mesopic Pupil Diameter (PD)
Percent change from baseline in study eye mesopic PD
Time frame: up to 15 days
| Milestone | Phentolamine Ophthalmic Solution 0.75% | Phentolamine Ophthalmic Solution Vehicle |
|---|---|---|
| Started | 71 | 73 |
| Completed | 68 | 73 |
| Not completed | 3 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
Percent of subjects with ≥ 15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (≥3 lines) of improvement in the study eye compared to baseline in monocular mLCVA at Day 8
| Participants | Phentolamine Ophthalmic Solution 0.75% | Phentolamine Ophthalmic Solution Vehicle |
|---|---|---|
| Percent of Subjects With 3 Lines mLCVA Improvement in Study Eye | 9 | 2 |
Percent of subjects with ≥ 5, ≥ 10, and ≥ 15 ETDRS letters (≥ 1, ≥ 2, and ≥ 3 lines, respectively) improvement compared to baseline in mLCVA at Day 8 (excluding the primary endpoint)
| Participants | Phentolamine Ophthalmic Solution 0.75% | Phentolamine Ophthalmic Solution Vehicle |
|---|---|---|
| Day 8 — >= 15 letters | 9 | 2 |
| Day 8 — 10-14 letters | 20 | 14 |
| Day 8 — 5-9 letters | 22 | 29 |
| Day 8 — Less than 5 | 19 | 28 |
| Day 15 — >= 15 letters | 14 | 2 |
| Day 15 — 10-14 letters | 16 | 15 |
| Day 15 — 5-9 letters | 28 | 39 |
| Day 15 — Less than 5 | 10 | 17 |
Percent of subjects with ≥ 5, ≥ 10, and ≥ 15 ETDRS letters (≥ 1, ≥ 2, and ≥ 3 lines, respectively) improvement compared to baseline in pLCVA and mHCVA at Day 8 and Day 15
| Participants | Phentolamine Ophthalmic Solution 0.75% | Phentolamine Ophthalmic Solution Vehicle |
|---|---|---|
| pLVCA Day 8 — >= 15 letters | 3 | 0 |
| pLVCA Day 8 — 10-14 letters | 12 | 9 |
| pLVCA Day 8 — 5-9 letters | 24 | 11 |
| pLVCA Day 8 — Less than 5 letters | 29 | 53 |
| pLVCA Day 15 — >= 15 letters | 7 | 1 |
| pLVCA Day 15 — 10-14 letters | 12 | 4 |
| pLVCA Day 15 — 5-9 letters | 22 | 20 |
| pLVCA Day 15 — Less than 5 letters | 23 | 46 |
| mHCVA Day 8 — >= 15 letters | 2 | 3 |
| mHCVA Day 8 — 10-14 letters | 5 | 3 |
| mHCVA Day 8 — 5-9 letters | 16 | 11 |
| mHCVA Day 8 — Less than 5 letters | 45 | 56 |
| mHCVA Day 15 — >= 15 letters | 3 | 5 |
| mHCVA Day 15 — 10-14 letters | 8 | 1 |
| mHCVA Day 15 — 5-9 letters | 19 | 14 |
| mHCVA Day 15 — Less than 5 letters | 34 | 51 |
Change from baseline in study eye mesopic PD
| millimeters | Phentolamine Ophthalmic Solution 0.75% | Phentolamine Ophthalmic Solution Vehicle |
|---|---|---|
| 8 Days, Change from Baseline | -1.081 ± 0.6931 | -0.130 ± 0.5608 |
| 15 Days, Change from Baseline | -1.083 ± 0.6556 | -0.121 ± 0.4673 |
Percent change from baseline in study eye mesopic PD
| percentage of change | Phentolamine Ophthalmic Solution 0.75% | Phentolamine Ophthalmic Solution Vehicle |
|---|---|---|
| 8 Days, Percent Change from Baseline | -17.98 ± 11.542 | -2.09 ± 9.492 |
| 15 Days, Percent Change from Baseline | -18.06 ± 11.418 | -1.75 ± 7.581 |
Collected over 15 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phentolamine Ophthalmic Solution 0.75% | 0/71 (0%) | 0/71 (0%) | 23/71 (32.4%) |
| Phentolamine Ophthalmic Solution Vehicle | 0/73 (0%) | 0/73 (0%) | 2/73 (2.7%) |
| Event | Phentolamine Ophthalmic Solution 0.75% | Phentolamine Ophthalmic Solution Vehicle |
|---|---|---|
| Instillation site painGeneral disorders | 9/71 | 0/73 |
| DysgeusiaNervous system disorders | 8/71 | 0/73 |
| Conjunctival HyperaemiaEye disorders | 6/71 | 2/73 |
| Instillation site erythemaGeneral disorders | 6/71 | 0/73 |
| Age, Continuous(years) | Phentolamine Ophthalmic Solution 0.75% | Phentolamine Ophthalmic Solution Vehicle | Total |
|---|---|---|---|
| Mean | 47 ± 14.14 | 45.4 ± 14.40 | 46.2 ± 14.24 |
| Sex: Female, Male(Participants) | Phentolamine Ophthalmic Solution 0.75% | Phentolamine Ophthalmic Solution Vehicle | Total |
|---|---|---|---|
| Female | 61 | 59 | 120 |
| Male | 9 | 14 | 23 |
| Race (NIH/OMB)(Participants) | Phentolamine Ophthalmic Solution 0.75% | Phentolamine Ophthalmic Solution Vehicle | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 0 | 3 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 5 | 8 |
| White | 66 | 64 | 130 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Phentolamine Ophthalmic Solution 0.75% | Phentolamine Ophthalmic Solution Vehicle | Total |
|---|---|---|---|
| United States | 70 | 73 | 143 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2020 to primary completion in May 2022, 16 months.
Results were first posted in Aug 2023, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Phentolamine
Opus Genetics, Inc